{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:01:40Z","timestamp":1790204500252,"version":"4.1.0"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                  <jats:p>Retinopathy of prematurity (ROP) is the leading avoidable and treatable cause of childhood blindness in the United States. The objective of this study was to evaluate trends of ROP screening, incidence, and treatment in US NICUs over the last 11 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Using standardized data submitted by NICUs from US Vermont Oxford Network member hospitals from 2008 to 2018 on very low birth weight infants hospitalized at the recommended age for ROP screening, we assessed trends in the proportion of eligible infants who received ROP screening, incidence, and treatment of ROP using logistic regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>This study included 381\u2009065 very low birth weight infants at 819 US NICUs participating in Vermont Oxford Network. Over time, more eligible infants received ROP screening (89% in 2008 to 91% in 2018, trend P &amp;lt; .001). Among those screened, overall ROP (stages 1\u20135, 37% in 2008 to 32% in 2018), severe ROP (stages 3\u20135, 8% in 2008 to 6% in 2018), and retinal ablation (6% in 2008 to 2% in 2018) declined and anti\u2013vascular endothelial growth factor injections (1% in 2012 to 2% in 2018) increased (all trend P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>Among US hospitals from 2008 to 2018, the proportion of ROP screening among infants hospitalized at the recommended age increased, less overall and severe ROP were reported, less retinal ablation was performed, and more anti\u2013vascular endothelial growth factor treatment was used. Despite increased ROP screening over time, 10% of infants were not screened, representing an opportunity for improvement in health care delivery.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2020-039966","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T08:26:06Z","timestamp":1620721566000},"source":"Crossref","is-referenced-by-count":37,"title":["Trends in Retinopathy of Prematurity Screening and Treatment: 2008\u20132018"],"prefix":"10.1542","volume":"147","author":[{"given":"S. Grace","family":"Prakalapakorn","sequence":"first","affiliation":[{"name":"Departments of Ophthalmology and"},{"name":"Pediatrics, Duke University, Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Vermont Oxford Network, Burlington, Vermont; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Vermont Oxford Network, Burlington, Vermont; and"},{"name":"Departments of Pediatrics and"},{"name":"Mathematics and Statistics, The University of Vermont, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.Y.","family":"Ehret","sequence":"additional","affiliation":[{"name":"Vermont Oxford Network, Burlington, Vermont; and"},{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"6","key":"2022010419571446600_B1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaapos.2012.09.004","article-title":"An update on progress and the changing epidemiology of causes of childhood blindness worldwide","volume":"16","author":"Kong","year":"2012","journal-title":"J AAPOS"},{"issue":"9","key":"2022010419571446600_B2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/archdischild-2016-310532","article-title":"Epidemiology of blindness in children. [published correction appears in Arch Dis Child. 2017;102(10):995]","volume":"102","author":"Solebo","year":"2017","journal-title":"Arch Dis Child"},{"issue":"4","key":"2022010419571446600_B3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2022010419571446600_B4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"2022010419571446600_B5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2022010419571446600_B6","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity. [published correction appears in Pediatrics. 2019;143(3):e20183810]","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"issue":"3","key":"2022010419571446600_B7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.21037\/tp.2019.07.01","article-title":"Vermont Oxford Network: a worldwide learning community","volume":"8","author":"Edwards","year":"2019","journal-title":"Transl Pediatr"},{"key":"2022010419571446600_B8","volume-title":"Manual of Operations: Part 1. Guidelines for Database Participation","author":"Vermont Oxford Network","year":"2016"},{"key":"2022010419571446600_B9","volume-title":"Vermont Oxford Network Database Manual of Operations","author":"Vermont Oxford Network","year":"2016"},{"key":"2022010419571446600_B10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2431-13-59","article-title":"A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr"},{"issue":"7","key":"2022010419571446600_B11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"2022010419571446600_B12","article-title":"2007\u20132008 natality public-use files","author":"National Center for Health Statistics"},{"issue":"3","key":"2022010419571446600_B13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1542\/peds.2007-0378","article-title":"Neonatologists\u2019 practices and experiences in arranging retinopathy of prematurity screening services","volume":"120","author":"Kemper","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"2022010419571446600_B14","doi-asserted-by":"crossref","first-page":"e164396","DOI":"10.1001\/jamapediatrics.2016.4396","article-title":"Variation in performance of neonatal intensive care units in the United States. [published correction appears in JAMA Pediatr. 2017;171(3):306]","volume":"171","author":"Horbar","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"11","key":"2022010419571446600_B15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"issue":"1","key":"2022010419571446600_B16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2004-1413","article-title":"The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study","volume":"116","author":"Good","year":"2005","journal-title":"Pediatrics"},{"issue":"7","key":"2022010419571446600_B17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2016.03.026","article-title":"Changes in course of retinopathy of prematurity from 1986 to 2013: comparison of three studies in the United States","volume":"123","author":"Quinn","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"2022010419571446600_B18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2014.1604","article-title":"Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity","volume":"132","author":"Quinn","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"2022010419571446600_B19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ophtha.2003.10.030","article-title":"Incidence of retinopathy of prematurity from 1996 to 2000: analysis of a comprehensive New York state patient database","volume":"111","author":"Chiang","year":"2004","journal-title":"Ophthalmology"},{"issue":"3","key":"2022010419571446600_B20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2009.04.018","article-title":"Incidence of retinopathy of prematurity in the United States: 1997 through 2005","volume":"148","author":"Lad","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2022010419571446600_B21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-039966\/1228996\/peds_2020039966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-039966\/1228996\/peds_2020039966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T19:57:39Z","timestamp":1641326259000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/147\/6\/e2020039966\/180274\/Trends-in-Retinopathy-of-Prematurity-Screening-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2020-039966","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"article-number":"e2020039966"}}